xcellon blue logo
Contact
Contact
xcellon blue logo

Accelerate Lead Selection
with Multiple Conjugation Pathways

Xcellon Biologics streamlines ADC & bioconjugate lead selection by integrating our enzymatic glycoengineering (EG) platform with a linker-payload toolbox. The EG platform enables precise site-specific conjugation by remodeling the Fc-glycan, generating homogeneous ADCs with defined DAR and improved stability. In addition, we offer a full range of conjugation chemistries including cysteine, lysine, enzymatic, and click-based methods, to match the unique needs of each program.

The Challenge with ADC Lead Selection

Lead selection is not one-size-fits-all. Some programs benefit from the uniformity of site-specific conjugation or glycoengineering, while others require the speed or flexibility of traditional conjugation methods. By combining both approaches with a comprehensive novel linker-payload toolbox, we ensure sponsors identify viable candidates with confidence, reducing downstream risk and accelerating time-to-clinic.

What We Offer

  • Linker-payload library
    Cleavable, non-cleavable, cathepsin-sensitive, lysosomal linkers paired with diverse payloads: tubulin inhibitors, DNA-damaging agents, topoisomerase inhibitors, protein degraders, and immune modulators.
  • Site-specific conjugation
    Via glycan remodeling (EG platform).
  • Alternative conjugation chemistries
    Cysteine, lysine, enzyme-catalyzed, click chemistry, and non-natural amino acid incorporation.
  • Analytical assessment
    DAR profiling, aggregation, stability, binding, cytotoxicity assay
  • Material Generation for In-Vivo Studies
    ADC production suitable for preclinical evaluation.

Lead candidates selected here transition directly into ADC development workflows for optimization and IND readiness. Stability and manufacturability insights also tie into Analytical & formulation development services, ensuring every candidate advances with data-driven confidence.

Evaluate ADC leads with both precision and flexibility

Evaluate ADC leads with precision and adaptability.
Gain actionable insights through robust characterization.
Confidently progress from discovery to development.

Contact us to start your lead selection

FAQs For ADC Lead Selection

What makes Xcellon’s lead selection approach different?
We combine our enzymatic glycoengineering (EG) platform for precise site-specific conjugation with the flexibility to apply other chemistries including cysteine, lysine, enzymatic, and click methods. This dual capability ensures both uniformity when it matters and adaptability when programs require alternative approaches.
What types of novel linker payloads and linkers can you screen?
Our toolbox includes cleavable, non-cleavable, lysosomal, and cathepsin-sensitive linkers, paired with novel linker payloads such as tubulin inhibitors, DNA-damaging agents, topoisomerase inhibitors, protein degraders, and immune modulators.
Can you provide ADC material for in vivo testing?
Yes, we generate small- to medium-scale conjugates suitable for preclinical evaluation, including animal studies.
xcellon white logo
Contact